Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Aug 15, 2026; 18(8): 121785
Published online Aug 15, 2026. doi: 10.4251/wjgo.v18.i8.121785
Published online Aug 15, 2026. doi: 10.4251/wjgo.v18.i8.121785
Table 7 Comparison of 30-day adverse events between the two groups, n (%)
| Item | P group (n = 40) | R group (n = 40) | Fisher’s exact test | P value |
| Pulmonary infection | 1 (2.50) | 0 (0.00) | ||
| Incision infection | 2 (5.00) | 1 (2.50) | ||
| Cerebral infarction | 1 (2.50) | 0 (0.00) | ||
| Loss of appetite | 1 (0.00) | 1 (2.50) | ||
| Intestinal obstruction | 0 (0.00) | 2 (5.00) | ||
| Total adverse events | 5 (12.50) | 4 (10.00) | 0.000 | 1.000 |
- Citation: Ma TT, Tong J, Liu MY. Cardioprotective effects of remimazolam in elderly hypertensive patients undergoing gastrointestinal tumor surgery: A randomized controlled trial. World J Gastrointest Oncol 2026; 18(8): 121785
- URL: https://www.wjgnet.com/1948-5204/full/v18/i8/121785.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i8.121785